Mind Medicine (mindmed) . Subordinate Voting Shares Stock News

Psilera is a Florida-based biotechnology company focused on developing drugs to treat mental disorders using non-hallucinogenic derivatives from psychedelic compounds. The company is aiming to allevi

Psychedelic-focused biotech company Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) recently met with the US Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDR

The usage of psychedelics like psilocybin, LSD, ketamine, and others are becoming more mainstream, especially with the initial steps to legalization getting moving across a number of states in the U.S

NEW YORK, Dec. 1, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, today a

Psychedelics-focused biotech company Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) announced the publication of its first data on the interaction of a selective serotonin uptake inhibitor,

Northern Trust Corp bought a new position in shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 218,858 shares of the companys stock, valued at approximately $755,000. A number of other large investors have also recently bought []

Zacks Investment Research downgraded shares of Mind Medicine (MindMed) (NASDAQ:MNMD) from a hold rating to a sell rating in a research note issued to investors on Thursday morning, Zacks.com reports. According to Zacks, Mind Medicine Inc. is a clinical-stage psychedelic medicine biotech company. It discovers, develops and deploys psychedelic inspired medicines and therapies to address [] The post Zacks Investment Research Lowers Mind Medicine (MindMed) (NASDAQ:MNMD) to Sell appeared first on ETF Daily News .

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) shares, rose in value on Friday, November 26, with the stock price down by -1.63% to the previous day’s close as strong demand from buyers drove the stock to $2.05. Actively observing the price movement in the recent trading, the stock is buoying the session at $2.08, falling within a … What Analysts Were Expecting After Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) fell -1.63% Read More »

During the last session, Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)s traded shares were 3.59 million. At the end of the trading day, the stocks price was $2.08, reflecting an intraday gain of 1.96% or $0.04. The 52-week high for the MNMD share is $5.77, that puts it down -177.4 from that peak though still a striking Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) Declined -11.49% Over The Last Month Are There Ways To Succeed From This Decline? Read More »

Charles Schwab Investment Management Inc. bought a new stake in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 682,800 shares of the companys stock, valued at approximately $2,356,000. Several other institutional investors also recently modified their holdings []

Charles Schwab Investment Management Inc. purchased a new stake in shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) in the second quarter, according to its most recent disclosure with the SEC. The firm purchased 682,800 shares of the companys stock, valued at approximately $2,356,000. A number of other hedge funds and other institutional investors have also []

California State Teachers Retirement System bought a new stake in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 444,272 shares of the companys stock, valued at approximately $1,533,000. Several other large investors also recently []

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)s traded shares stood at 5.42 million during the last session. At the close of trading, the stocks price was $2.12, to imply a decrease of -5.36% or -$0.12 in intraday trading. The MNMD shares 52-week high remains $5.77, putting it -172.17% down since that peak but still an impressive 51.42% Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) Stock Dropped -10.55% Over A Month Any Room To Run? Read More »

Psychedelic drugs could be a major game-changer when it comes to treating mental illness. All as psilocybin, LSD, and MDMA show progress.

MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a biotech company developing psychedelic-inspired therapies, announced its financial results late Monday for the third quarter ended Sept. 30, 2021. Q3 &